Single-Boosted Protease Inhibitor versus Double-Boosted Protease Inhibitors for the Salvage Therapy in HIV-Infected Patients

Abstract

Objective: To compare treatment outcomes between the regimens of single-boosted protease inhibitor (PI) and double-boosted PIs for the salvage therapy in patients who failed nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens. Methods: A total of 64 patients from 2 cohorts, 40 in twice daily ritonavir-boosted lopinavir (LPV/r) at 400/100 mg plus lamivudine (3TC) and 24 in once daily ritonavir-boosted atazanavir and saquinavir (ATV/SQV/r) at 300/1600/100 mg/d, were studied. Results: At 48 weeks, 30 (75%) patients in LPV/r group and 20 (83%) patients in ATV/SQV/r group achieved HIV-1 RNA at <400 copies/mL (P = .790). In all, 24 (60%) and 16 (67%) achieved HIV-1 RNA at <50 copies/mL (P = .541). Low-level viral rebound (51-400 copies/mL) was found in 6 (15%) in LPV/r group and 4 (17%) in ATV/SQV/r group (P = 1.000). Medians CD4 counts were 336 cells/mm³ and 330 cells/mm³ in the corresponding groups (P = 0.937). Conclusion: No additional benefit is found with double-boosted PIs compared to single-boosted PI in terms of treatment responses in HIV-infected patients failing NNRTI-based regimen.

Keywords

HIV boosted protease inhibitors resistance salvage Thailand

References

Guideline for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and the Henry J. Kaiser Family Foundation; 2009 .

Gazzard BG , Anderson J. , Babiker A. , et al. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 2008;9(8):563-608.

Hammer SM , Eron JJ, Jr , Reiss P. , et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA. 2008;300(5):555-570.

Sungkanuparph S. , Manosuthi W. , Kiertiburanakul S. , Piyavong B. , Chumpathat N. , Chantratita W. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis. 2007;44(3):447-452.

Staszewski S. , Babacan E. , Stephan C. , et al. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother. 2006;58(5):1024-1030.

Hellinger J. , Morris A. , Piscitelli S. , et al. Pilot study of saquinavir-SGC (Fortovase, SQV) 1000 mg twice daily and lopinavir/ritonavir (Kaletra, LPV/r) in protease inhibitor-experienced HIV+ individuals: dose escalation and combined normalized inhibitory quotient (cNIQ). In: 9th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2002. http://www.retroconference.org/2002/Srchfrm.htm .

Manosuthi W. , Kiertiburanakul S. , Amornnimit W. , et al. Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. AIDS Res Ther. 2009;6:30.

Manosuthi W. , Sungkanuparph S. , Ruxrungtham K. , et al. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir . J Acquir Immune Defic Syndr. 2008;47(1):127-129.

Ribera E. , Curran A. Double-boosted protease inhibitor antiretroviral regimens: what role? Drugs. 2008;68(16):2257-2267.

10.

Boffito M. , Maitland D. , Samarasinghe Y. , Pozniak A. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis. 2005;18(1):1-7.

11.

Chetchotisakd P. , Anunnatsiri S. , Mootsikapun P. , et al. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors . HIV Med. 2007;8(8):529-535.

12.

Gilliam BL , Chan-Tack KM , Qaqish RB , Rode RA , Fantry LE , Redfield RR Successful treatment with atazanavir and lopinavir/ ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients. AIDS Patient Care STDS. 2006;20(11):745-759.

13.

Winston A. , Mallon PW , Satchell C. , et al. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Clin Infect Dis. 2007;44(11):1475-1483.

14.

Vernazza P. , Daneel S. , Schiffer V. , et al. The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Mono-maintenance (ATARITMO) Trial . AIDS. 2007;21(10):1309-1315.

15.

Palmer S. , Maldarelli F. , Wiegand A. , et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2008;105(10):3879-3884.

16.

Arribas JR , Pulido F. , Delgado R. , et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr. 2005;40(3):280-287.

17.

Escobar I. , Pulido F. , Perez E. , Arribas JR , Garcia MP , Hernando A. Pharmacoeconomic analysis of a maintenance strategy with lopinavir/ritonavir monotherapy in HIV-infected patients [in Spanish]. Enferm Infecc Microbiol Clin. 2006;24(8):490-494.

18.

Cameron DW , da Silva BA , Arribas JR , et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy . J Infect Dis. 2008;198(2):234-240.

19.

Riddler SA , Haubrich R. , DiRienzo AG , et al. Class-sparing regimens for initial treatment of HIV-1 infection . N Engl J Med. 2008; 358(20):2095-2106.

20.

Bartlett JA , Fath MJ , Demasi R. , et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006;20(16):2051-2064.

21.

Siripassorn K. , Manosuthi W. , Chottanapund S. , et al. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting . AIDS Res Hum Retroviruses. 2010;26(2):139-148.

22.

Currier JS , Lundgren JD , Carr A. , et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Circulation. 2008; 118(6):e29-e35.

23.

Croom KF , Dhillon S. , Keam SJ Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009;69(8): 1107-1140.

24.

Castagna A. , Danise A. , Menzo S. , et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006; 20(6):795-803.

25.

Yazdanpanah Y. , Fagard C. , Descamps D. , et al. High rate of virologic suppression with raltegravir plus etravirine and darunavir/ ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. Clin Infect Dis. 2009;49(9):1441-1449.